Holen Sie sich die Stockscreener-App
15.42
2.46%
0.37
Handel nachbörslich:
15.50
0.08
+0.52%
Schlusskurs vom Vortag:
$15.05
Offen:
$15.03
24-Stunden-Volumen:
445.77K
Relative Volume:
1.37
Marktkapitalisierung:
$373.22M
Einnahmen:
$39.30M
Nettoeinkommen (Verlust:
$-41.20M
KGV:
-7.3429
EPS:
-2.1
Netto-Cashflow:
$-39.61M
1W Leistung:
+43.58%
1M Leistung:
+75.63%
6M Leistung:
+67.25%
1J Leistung:
-12.44%
1-Tages-Spanne:
$14.82
$15.49
1-Wochen-Bereich:
$10.47
$15.77
52-Wochen-Spanne:
$6.40
$33.13
Cvrx Inc Stock (CVRX) Company Profile
Firmenname
Cvrx Inc
Sektor
Branche
Telefon
(763) 416-2850
Adresse
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-11 | Bestätigt | Lake Street | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2024-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Lake Street | Buy |
| 2022-07-18 | Eingeleitet | Craig Hallum | Buy |
| 2021-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-26 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cvrx Inc Aktie (CVRX) Neueste Nachrichten
Craig Hallum Issues Positive Forecast for CVRx (NASDAQ:CVRX) Stock Price - MarketBeat
CVRx earns Medicare win for Barostim procedure - Mass Device
CVRx gains CMS payment classification for Barostim - Investing.com
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 - GlobeNewswire
Emerald Mutual Fund Advisers Trust Has $2.54 Million Stock Holdings in CVRx, Inc. (NASDAQ:CVRX) - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Call Transcript - MSN
FY2024 EPS Estimates for CVRx Lowered by Cantor Fitzgerald - MarketBeat
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report - Simply Wall St
CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
How the (CVRX) price action is used to our Advantage - Stock Traders Daily
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results By Investing.com - Investing.com South Africa
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results - Investing.com
Earnings call: CVRx reports robust Q3 growth, eyes future reimbursement wins - Investing.com India
Canaccord Genuity Group Increases CVRx (NASDAQ:CVRX) Price Target to $17.00 - MarketBeat
CVRx (NASDAQ:CVRX) Given "Overweight" Rating at Piper Sandler - MarketBeat
CVRx Reports Strong Revenue Growth in Q3 2024 - TipRanks
CVRx earnings missed by $0.10, revenue topped estimates - Investing.com Canada
CVRx: Q3 Earnings Snapshot - The Advocate
CVRx Reports Third Quarter 2024 Financial and Operating Results - GlobeNewswire
CVRx Inc Q3 2024 Earnings: Revenue Hits $13.4M, EPS at -$0.57, S - GuruFocus.com
CVRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CVRx (CVRX) Price Target Increased by 10.54% to 33.15 - MSN
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com South Africa
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - Investing.com India
CVRx (NASDAQ:CVRX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Cantor Fitzgerald stays positive on CVRx, reaffirms $14 stock PT after survey - Investing.com
CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
CVRx (CVRX) Set to Announce Earnings on Tuesday - MarketBeat
CVRx, Inc. Shares Surge Following Key Heart Failure Treatment Approval - Stocks Telegraph
CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Canaccord maintains Buy rating on CVRx stock - Investing.com
Canaccord maintains Buy rating on CVRx stock By Investing.com - Investing.com UK
CVRx announces new CPT Category I codes for Barostim heart failure therapy - Yahoo Finance
AMA approves new codes for heart failure therapy By Investing.com - Investing.com Australia
CVRx announces new CPT Category I codes for Barostim - Yahoo Finance
AMA approves new codes for heart failure therapy - Investing.com
CVRx announces new CPT® Category I codes for Barostim - The Manila Times
CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024 - The Manila Times
Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX) - Simply Wall St
(CVRX) Technical Data - Stock Traders Daily
CVRx secures additional $20 million loan tranche By Investing.com - Investing.com Australia
CVRx secures additional $20 million loan tranche - Investing.com India
Finanzdaten der Cvrx Inc-Aktie (CVRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cvrx Inc-Aktie (CVRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SLATTERY JOSEPH P | Director |
Aug 08 '24 |
Buy |
8.24 |
3,000 |
24,716 |
27,645 |
| SLATTERY JOSEPH P | Director |
Aug 06 '24 |
Buy |
9.09 |
2,500 |
22,725 |
24,645 |
| Hykes Kevin | PRES & CEO |
Aug 05 '24 |
Buy |
8.36 |
30,000 |
250,767 |
30,000 |
0.47%
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):